A phase Ib/II trial enrolled a small number of patients with HER2 negative breast cancer to investigate the safety and efficacy of nab paclitaxel + alpelisib; the results showed promising efficacy, especially in PI3K mutated tumours. The gene discussed is PIK3CA; the disease is breast cancer.